NCT05028218 - A Clinical Study of TQB3824 in Subjects With Advanced Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions

Advanced Cancer

Interventions

DRUG

TQB3824 tablets

TQB3824 is a CDC7 inhibitor, which plays important roles in the maintenance of DNA replication forks and DNA damage response pathways.

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institution & Hospital, Tianjin